Q4 2022 Results

Company overview Financial review 2023 priorities Appendix Novartis delivers robust core operating income growth and core margin expansion; achieves important innovation milestones STRATEGY Growth, cc Group sales Q4 +3% (FY +4%) IM sales Q4 +3% (FY +4%); US IM sales Q4 +7% Sandoz sales Q4 +0% (FY +4%) 1 Innovation Pluvicto EU approval for mCRPC post-taxane Iptacopan Ph3 APPOINT-PNH met primary endpoint Pluvicto Ph3 PSMAfore in mCRPC pre-taxane met primary endpoint lanalumab Ph3 initiated in wAIHA; Ph3 initiating in 1L ITP and 2L ITP 3 Productivity, cc Group core operating income Q4 +15% (FY +8%) IM core operating income Q4 +14% (FY +8%) IM core margin Q4 36.4%, +3.5%pts (FY 36.9%) Sandoz core operating income Q4 -18% (FY -1%) SG&A savings of ~USD 1.5bn to be fully embedded by 20242 2 ESG 4 Sustainability Linked Bond: Significant progress towards 2025 targets Innovative Therapies in LMICS: ~1.2m patients; +26.3% vs. 2021 Novartis flagship programs: ~31m patients vs. 2025 target ~23m Ratings: CDP - AA score¹; ATMI: Leaders group 10th consecutive year Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 49 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. IM - Innovative Medicines division. mCRPC metastatic castration-resistant prostate cancer. WAIHA - warm autoimmune hemolytic anemia. ITP immune thrombocytopenia. LMIC low and middle income countries. CDP carbon disclosure project. ATMI - Access to Medicine Index. 1. One of only two pharma companies with AA rating. 2. Relating to streamlined organizational model. 4 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation